Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
Status:
Unknown status
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Metabolic and Molecular Response evaluation for the individualization of therapy in
adenocarcinomas of the gastroesophageal junction by evaluation of the R0 resection rate for
patients with metabolically (ie, according to PET criteria) chemotherapy-resistant locally
advanced AEG, who receive an intensified neoadjuvant chemoradiotherapy (INRCT). Additonal
efforts will be done by investigation of molecular and metabolic biomarkers in relation to
their predictive and prognostic value by correlating them with histopathologic responses and
clinical outcome in an exploratory approach.